youtube_live
Q3 2026 earnings • released • EPS beat +11,38% • Revenue beat +7,33%
See resultschevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
31,38 USD
arrow_upward
+6,70%(+1,97) 1D
31,98 USD
arrow_upward
+1,91% (+0,60)bedtimeAfter hours
Closed: 9-ноя., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
29,32 USD
High
31,44 USD
Low
28,93 USD
Mkt. cap
1,87 млд
Avg. vol.
1,29 млн
Volume
0,00
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-7,01 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
29,32 USD
High
31,44 USD
Low
28,93 USD
Mkt. cap
1,87 млд
Avg. vol.
1,29 млн
Volume
0,00
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-7,01 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Bloomberg.com
·
1 күн мурун
Watch 95% S&P 500, 5% Bitcoin in New Franklin ETF: Drilldown
Investing.com
·
8 саат мурун
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.15%
24/7 Wall St.
·
11 саат мурун
Verizon’s Dividends Kept $1,000 Afloat at $1,580 While the S&P 500 Reached $3,910
StoneX
·
14 саат мурун
S&P 500 Forecast: SPX rises despite Nvidia’s decline
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc